WuXi Biologics, a global open-access biologics technology platform company, announced that the construction of new biologics drug substance manufacturing facility has commenced on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth in Ireland.
It’s the company’s first site outside of China and is supported by the Irish government through IDA Ireland.
The facility is designed to run both traditional fed-batch or perfusion process and continuous bioprocessing, a next generation manufacturing technology to be first implemented globally in the 64-acre campus. When completed, a total capacity of 48,000L fed-batch and 6,000L perfusion will be installed, representing one of the world’s largest facilities using single-use bioreactors.
Company CEO Dr. Chris Chen said the facility “symbolizes the significant start of our global biomanufacturing network.” WuXi Biologics is headquartered in Wuxi city, Jiangsu province, China.
(Source: WuXi Biologics)